Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer
The benefit of combined CDK4/6 and anti-HER2 therapy in breast cancer is limited due to acquired resistance. Here, the authors perform single-cell analysis and show an immature myeloid cell population to infiltrate resistant tumors, and that combined cabozantinib and checkpoint therapy overcome this...
Guardado en:
Autores principales: | Qingfei Wang, Ian H. Guldner, Samantha M. Golomb, Longhua Sun, Jack A. Harris, Xin Lu, Siyuan Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c38f32d16a5646e1b6161ac0f8f636b7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Fulvestrant in Combination with CDK4/6 Inhibitors for HER2- Metastatic Breast Cancers: Current Perspectives
por: Iorfida M, et al.
Publicado: (2020) -
Place of CDK 4/6 and PARP inhibitors in the modern treatment approach of HER2-negative breast cancer
por: Board Editorial
Publicado: (2021) -
Effective combinatorial immunotherapy for penile squamous cell carcinoma
por: Tianhe Huang, et al.
Publicado: (2020) -
Editorial: Immunotherapy as an Evolving Approach for the Treatment of Breast Cancer
por: Mai F. Tolba, et al.
Publicado: (2021) -
Quantifying CDK inhibitor selectivity in live cells
por: Carrow I. Wells, et al.
Publicado: (2020)